Researcher.Life Logo

Annals of Pharmacotherapy : Impact Factor & More

eISSN: 1542-6270pISSN: 1060-0280

Aims and Scope of Annals of Pharmacotherapy

The Annals of Pharmacotherapy is a peer-reviewed medical journal covering all aspects of pharmacotherapy. The journal was established in 1967 as Drug Intelligence. The name changed a few times during its history, to Drug Intelligence and Clinical Pharmacy (DICP) in 1969 and DICP-The Annals of Pharmacotherapy in 1989, before obtaining its current name in 1992. Less

Key Metrics

CiteScore
5
H-Index
120
Impact Factor
< 5
SJR
Q1Pharmacology (medical)
SNIP
1.15
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Annals of Pharmacotherapy

Annals of Pharmacotherapy Journal Specifications

Overview
Publisher SAGE PUBLICATIONS INC
Language Multi-Language
Frequency Monthly
General Details
LanguageMulti-Language
FrequencyMonthly
Publication Start Year1967
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Annals of Pharmacotherapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Annals of Pharmacotherapy

Evaluation of a Pharmacist-Led Intravenous Iron Therapy Transitions of Care Service in Heart Failure.
  • 1 Jun 2026
  • The Annals of pharmacotherapy
Newly Escalated Psychotropic Medications in the Trauma Intensive Care Unit: Prescribing Patterns During Care Transitions.
  • 1 Jun 2026
  • The Annals of pharmacotherapy
Evaluation of Nurse-Managed Heparin Nomogram Adherence After Implementation of an Electronic Health Record-Embedded Heparin Calculator: An Antithrombotic Stewardship Initiative.
  • 1 Jun 2026
  • The Annals of pharmacotherapy
Relieving the Weight: Fenfluramine's Re-emergence as Antiseizure Medication for Lennox-Gastaut and Dravet Syndrome.
  • 1 Jun 2026
  • The Annals of pharmacotherapy
Assessment of Guideline-Directed Medical Therapy Optimization Scores and Readmission Risk in Heart Failure With Reduced Ejection Fraction.
  • 1 Jun 2026
  • The Annals of pharmacotherapy
Pyzchiva (ustekinumab-ttwe): A New Biosimilar for Psoriasis.
  • 1 Jun 2026
  • The Annals of pharmacotherapy
Evaluation of a Pharmacist-Led Intravenous Iron Therapy Transitions of Care Service in Heart Failure.
  • 1 Jun 2026
  • The Annals of pharmacotherapy
Newly Escalated Psychotropic Medications in the Trauma Intensive Care Unit: Prescribing Patterns During Care Transitions.
  • 1 Jun 2026
  • The Annals of pharmacotherapy
Evaluation of Nurse-Managed Heparin Nomogram Adherence After Implementation of an Electronic Health Record-Embedded Heparin Calculator: An Antithrombotic Stewardship Initiative.
  • 1 Jun 2026
  • The Annals of pharmacotherapy
Relieving the Weight: Fenfluramine's Re-emergence as Antiseizure Medication for Lennox-Gastaut and Dravet Syndrome.
  • 1 Jun 2026
  • The Annals of pharmacotherapy
Assessment of Guideline-Directed Medical Therapy Optimization Scores and Readmission Risk in Heart Failure With Reduced Ejection Fraction.
  • 1 Jun 2026
  • The Annals of pharmacotherapy
Pyzchiva (ustekinumab-ttwe): A New Biosimilar for Psoriasis.
  • 1 Jun 2026
  • The Annals of pharmacotherapy

FAQs on Annals of Pharmacotherapy